Literature DB >> 19725030

Promoter variants of the cannabinoid receptor 1 gene (CNR1) in interaction with 5-HTTLPR affect the anxious phenotype.

Judit Lazary1, Aron Lazary, Xenia Gonda, Anita Benko, Eszter Molnar, Laszlo Hunyady, Gabriella Juhasz, Gyorgy Bagdy.   

Abstract

Anxiety is a polygenic condition, and the recently discovered Endocannabinoid System (ECS) is one plausible candidate. Experimental data suggest that the ECS can modulate several neurotransmitter systems, including the serotonergic system, which itself plays a significant role in anxiety. However, to date there is no evidence of gene-gene interactions; indeed genetic studies focusing separately on the two systems provide conflicting data. Thus, the aim of our study was to analyze the interaction of the promoter regions of the serotonin transporter (SLC6A4) and cannabinoid receptor 1 (CNR1) genes on anxiety. We genotyped 706 individuals for the 5-HTTLPR in the SLC6A4 promoter and 4 SNPs located in the CNR1 promoter region. Anxiety was measured by the State-Trait Anxiety Inventory (STAI-S, STAI-T), the anxiety subscale of TEMPS-A (TEMPS-Anx), and the Brief Symptom Inventory (BSI-Anx). Significant 5-HTTLPR x CNR1 promoter-promoter interaction was observed using STAI-T (P = 0.0006) and TEMPS-Anx (P = 0.0013). The risk of high anxiety scores on BSI-Anx was 4.6-fold greater in homozygous 'GG' rs2180619 in combination with homozygous 'SS' 5-HTTLPR (P = 0.0005) compared to other genotypes. The effect of previously described "TGC" haplotype in the alternative promoter of CNR1 depended both on the conventional promoter polymorphism and the 5-HTTLPR. Our haplotype and putative transcription binding profile analyses strongly suggest that certain constellations of CB1-receptor and 5-HTT promoters yield extremely high or low synaptic 5-HT concentrations, and these are associated with an anxious phenotype. In conclusion, genetically determined serotonergic and endocannabinoid dysfunctions could lead to a vulnerability causing anxiety disorders and possibly depression. 2009 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19725030     DOI: 10.1002/ajmg.b.31024

Source DB:  PubMed          Journal:  Am J Med Genet B Neuropsychiatr Genet        ISSN: 1552-4841            Impact factor:   3.568


  23 in total

Review 1.  Regulation of endocannabinoid release by G proteins: a paracrine mechanism of G protein-coupled receptor action.

Authors:  Pál Gyombolai; Dorottya Pap; Gábor Turu; Kevin J Catt; György Bagdy; László Hunyady
Journal:  Mol Cell Endocrinol       Date:  2011-11-02       Impact factor: 4.102

Review 2.  CB1 and CB2 Receptor Pharmacology.

Authors:  Allyn C Howlett; Mary E Abood
Journal:  Adv Pharmacol       Date:  2017-06-12

Review 3.  Contributions of endocannabinoid signaling to psychiatric disorders in humans: genetic and biochemical evidence.

Authors:  C J Hillard; K M Weinlander; K L Stuhr
Journal:  Neuroscience       Date:  2011-11-17       Impact factor: 3.590

Review 4.  Opposing local effects of endocannabinoids on the activity of noradrenergic neurons and release of noradrenaline: relevance for their role in depression and in the actions of CB(1) receptor antagonists.

Authors:  E Kirilly; L Hunyady; G Bagdy
Journal:  J Neural Transm (Vienna)       Date:  2012-09-19       Impact factor: 3.575

5.  Short-term adaptation of conditioned fear responses through endocannabinoid signaling in the central amygdala.

Authors:  Kornelia Kamprath; Hector Romo-Parra; Martin Häring; Stefano Gaburro; Michael Doengi; Beat Lutz; Hans-Christian Pape
Journal:  Neuropsychopharmacology       Date:  2010-10-27       Impact factor: 7.853

6.  Acetaminophen differentially enhances social behavior and cortical cannabinoid levels in inbred mice.

Authors:  Georgianna G Gould; Alexandre Seillier; Gabriela Weiss; Andrea Giuffrida; Teresa F Burke; Julie G Hensler; Crystal Rock; Amanda Tristan; Lance R McMahon; Alexander Salazar; Jason C O'Connor; Neera Satsangi; Rajiv K Satsangi; Ting-Ting Gu; Keenan Treat; Corey Smolik; Stephen T Schultz
Journal:  Prog Neuropsychopharmacol Biol Psychiatry       Date:  2012-04-21       Impact factor: 5.067

Review 7.  Developmental regulation of fear learning and anxiety behavior by endocannabinoids.

Authors:  T T-Y Lee; M N Hill; F S Lee
Journal:  Genes Brain Behav       Date:  2015-11-05       Impact factor: 3.449

8.  Long-term CB₁ receptor blockade enhances vulnerability to anxiogenic-like effects of cannabinoids.

Authors:  Simone Tambaro; Maria Lauda Tomasi; Marco Bortolato
Journal:  Neuropharmacology       Date:  2013-02-24       Impact factor: 5.250

9.  Dose-dependent cannabis use, depressive symptoms, and FAAH genotype predict sleep quality in emerging adults: a pilot study.

Authors:  Kristin E Maple; Kymberly A McDaniel; Skyler G Shollenbarger; Krista M Lisdahl
Journal:  Am J Drug Alcohol Abuse       Date:  2016-04-13       Impact factor: 3.829

10.  The contributions of the endocannabinoid system and stress on the neural processing of reward stimuli.

Authors:  F M Filbey; D Beaton; S Prashad
Journal:  Prog Neuropsychopharmacol Biol Psychiatry       Date:  2020-11-20       Impact factor: 5.067

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.